FDA accepts GSK’s RSV vaccine for adults aged 50-59 for review

07 Feb 2024
www.pharmaceutical-technology.com
Phase 3Drug ApprovalVaccinePriority ReviewClinical Result
FDA accepts GSK’s RSV vaccine for adults aged 50-59 for review
Preview
Source: Pharmaceutical Technology
A decision on GSK’s RSV vaccine use in adults aged 50-59 years is expected in June 2024. Credit: Golden Shrimp / Shutterstock.com.
The US Food and Drug Administration (FDA) has accepted for review a supplemental Biologics Licence Application to expand the usage of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years.
The vaccine is already in use in the US for individuals aged 60 years and above to prevent RSV-associated lower respiratory tract disease (LRTD).
The application is backed by positive outcomes from a Phase III clinical trial, which assessed the vaccine’s immune response and safety in the target age group. These subjects included those with underlying health conditions and hence increased risk for RSV-LRTD.
GSK utilised a Priority Review Voucher to reduce the FDA review period by four months.
A decision on the approval under the Prescription Drug User Fee Act is expected from the FDA on 7 June 2024.
See Also:Regeneron’s linvoseltamab application accepted for review
FDA accepts GSK’s RSV vaccine for adults aged 50-59 for review
Preview
Source: Pharmaceutical Technology
As England’s virus hospitalisations surge flu vaccines evolve
FDA accepts GSK’s RSV vaccine for adults aged 50-59 for review
Preview
Source: Pharmaceutical Technology
The adjuvanted vaccine contains the RSVPreF3 antigen, a recombinant glycoprotein F stabilised in the prefusion conformation, paired with the company’s AS01E adjuvant.
If approved, Arexvy will become the first vaccine available for RSV prevention in this age group.
The vaccine is also approved in countries, including Japan, Europe, the UK and Canada for RSV-LRTD prevention in people aged 60 years and above.
The European Medicines Agency (EMA) accepted GSK’s regulatory application in January 2024.
GSK has also reported that the China National Medical Products Administration’s Center for Drug Evaluation (CDE) is reviewing a regulatory application for Shingrix (recombinant zoster vaccine (RZV)) for shingles prevention in adults.
A non-live, recombinant subunit adjuvanted vaccine, Shingrix received initial approval for use in adults aged 50 years and above in 2019.
The application for the expanded use is based on data from six trials involving patients who have undergone stem cell or kidney transplantation or have blood cancer, a solid tumour or human immunodeficiency virus.
Shingrix combines the glycoprotein E antigen with the AS01B adjuvant system and is designed to overcome the natural decline in immunisation response associated with ageing.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.